BioSpace News Archive

IceCure Medical Ltd. announced that it will release its financial and operational results for the three months ended March 31, 2023 with a press release prior to the market open on Monday, May 22, 2023 and will host a conference call at 10:00 a.m. ET that day to discuss the results and corporate developments.

Sling Therapeutics, Inc. today announced the presentation of preclinical data that demonstrate linsitinib, a small molecule insulin-like growth factor I receptor (IGF-1R) inhibitor, decreases immune response in a mouse model of TED when given prophylactically or therapeutically.

Seelos Therapeutics, Inc. today provided a clinical update and reported its financial results for the first quarter ended March 31, 2023.

Mozart Therapeutics today announced the presentation of data at the American Association of Immunologists (AAI) Annual Meeting demonstrating the potential of its lead therapeutic, a targeted, bispecific CD8 Treg modulator, as a new therapeutic treatment approach for autoimmune diseases.

BiOneCure Therapeutics, Inc. has announced a strategic collaboration with Nanjing Leads Biolabs to develop a range of innovative anti-drug conjugates (ADCs) for treating solid tumors.

Melinta Therapeutics, LLC (Melinta) and Xediton Pharmaceuticals Inc (Xediton) today announced they have entered into an exclusive commercialization and licensing agreement for BAXDELA ® (delafloxacin), KIMYRSA ® (oritavancin), ORBACTIV ® (oritavancin) and VABOMERE ® (meropenem and vaborbactam), four novel anti-infective products.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that once-daily AUSTEDO XR (deutetrabenazine) extended-release tablets are now available for adults in the United States in 6 mg, 12 mg and 24 mg tablet strengths.

Equillium, Inc. today announced a poster was presented over the weekend at IMMUNOLOGY2023, the annual meeting of The American Association of Immunologists.

Quantum-Si Incorporated, The Protein Sequencing Company™, announced the election of Scott Mendel, former President and Chief Executive Officer of GenMark Diagnostics, Inc., to its Board of Directors.

bioAffinity Technologies, Inc. today reported financial results for the three months ended March 31, 2023.